George Scangos is back in the Bay Area, targeting HIV and other infectious diseases.
The former Exelixis Inc. CEO — who spent the past six-plus years leading Boston-area biotech Biogen Inc. (NASDAQ: BIIB) — is CEO of Vir Biotechnology Inc. The startup is backed by $150 million from Arch Venture Partners, an equity investment from the Bill & Melinda Gates Foundation and other unspecified investors.
Vir's headquarters and a lab operation will be in the Bay Area — Scangos was scouting sites…
George Scangos is back in the Bay Area, targeting HIV and other infectious diseases.
The former Exelixis Inc. CEO — who spent the past six-plus years leading Boston-area biotech Biogen Inc. (NASDAQ: BIIB) — is CEO of Vir Biotechnology Inc. The startup is backed by $150 million from Arch Venture Partners, an equity investment from the Bill & Melinda Gates Foundation and other unspecified investors.
Vir's headquarters and a lab operation will be in the Bay Area — Scangos was scouting sites…